Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Cabiralizumab in Relapsed/Refractory Peripheral T Cell Lymphoma
NCT03927105Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Apr 2019
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabiralizumab in peripheral T-cell lymphoma (PTCL), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Overall Response Rate at 4 months and Complete Response Rate at 4 months. Started Apr 2019; status: completed.
02
Drugs
cabiralizumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03927105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927105.